<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="157964">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01760993</url>
  </required_header>
  <id_info>
    <org_study_id>SPD489-336</org_study_id>
    <secondary_id>2012-003920-18</secondary_id>
    <nct_id>NCT01760993</nct_id>
  </id_info>
  <brief_title>Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia</brief_title>
  <official_title>A Phase 3, Long-term, Open-label, Multicenter, 52-week, Flexible-dose Safety Study of SPD489 as Adjunctive Treatment to Established Maintenance Doses of Antipsychotic Medications on Negative Symptoms in Clinically Stable Adults Who Have Persistent Predominant Negative Symptoms of Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine if the long-term use of  SPD489 (40, 80,
      100, 120, 140, and 160mg) administered as a daily morning is safe and tolerable.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Not required
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study was discontinued due to non-safety related business prioritization decisions. No
    subjects were randomized.
  </why_stopped>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Scores at 52 Weeks</measure>
    <time_frame>Basline and 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Cognitive Test Battery (CogState Battery) Score at 52 Weeks</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Columbia-Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) at 52 Weeks</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Simpson Angus Scale (SAS) Total Score at 52 Weeks</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Barnes Akathisia Scale (BAS) Total Score at 52 Weeks</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in the Abnormal Involuntary Movement Scale (AIMS) at 52 Weeks</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Clinical Evaluation of Harmful Behavior (CEHB) Scale at 52 Weeks</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Amphetamine Cessation Symptom Assessment (ACSA) Total Score at 52 Weeks</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Negative Symptom Assessment (NSA-16) Total Score at 52 Weeks</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Personal and Social Performance (PSP) Scale Score at 52 Weeks</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression-Schizophrenia Severity of Illness (CGI-SCH-S) Scale</measure>
    <time_frame>Baseline and week 52</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression-Schizophrenia Degree of Change (CGI-SCH-C) Scale</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Social Functioning Scale (SFS) at 52 Weeks</measure>
    <time_frame>Baseline and 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>SPD489</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPD489</intervention_name>
    <description>Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks</description>
    <arm_group_label>SPD489</arm_group_label>
    <other_name>lisdexamfetamine dimesylate, LDX, Vyvanse</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 to 65 years of age

          -  Has a reliable  informant (eg, family member, social worker, caseworker, or nurse
             that spends &gt;4 hours/week with the subject)

          -  Fixed home/place of residence and can be reached by telephone

          -  On a stable dose of antipsychotic medications

          -  Able to swallow capsules

        Exclusion Criteria:

          -  -Taking lithium, carbamazepine, lamotrigine, gabapentin, cholinesterase inhibitors,
             modafinil, or other stimulants such as methylphenidate and other amphetamine products

          -  Treated with clozapine in past 30 days

          -  Lifetime history of stimulant, cocaine, or amphetamine abuse or dependence

          -  History of seizures (other than infantile febrile seizures), any tic disorder, or
             current diagnosis and/or a known family history of Tourette's Disorder, serious
             neurological disease, history of significant head trauma, dementia, cerebrovascular
             disease, Parkinson's disease, or intracranial lesions

          -  Uncontrolled hypertension

          -  History of thyroid disorder that has not been stabilized on thyroid medication

          -  Glaucoma

          -  Pregnant or nursing

          -  Subject has received an investigational product or participated in a clinical study
             within 30 days
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen R. Marder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Desert Pacific Mental Illness Research, Education, and Clinical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SP Research PLLC/Oklahoma Clinical Research Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRI Lifetree</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 1, 2014</lastchanged_date>
  <firstreceived_date>January 2, 2013</firstreceived_date>
  <firstreceived_results_date>May 1, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Not Required</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Dextroamphetamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>SPD489</title>
          <description>SPD489: Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized</population>
      <group_list>
        <group group_id="B1">
          <title>SPD489</title>
          <description>SPD489: Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Scores at 52 Weeks</title>
        <time_frame>Basline and 52 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized</population>
        <group_list>
          <group group_id="O1">
            <title>SPD489</title>
            <description>SPD489: Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Scores at 52 Weeks</title>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Cognitive Test Battery (CogState Battery) Score at 52 Weeks</title>
        <time_frame>Baseline and 52 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized</population>
        <group_list>
          <group group_id="O1">
            <title>SPD489</title>
            <description>SPD489: Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Cognitive Test Battery (CogState Battery) Score at 52 Weeks</title>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Columbia-Suicide Severity Rating Scale (C-SSRS)</title>
        <time_frame>Up to 52 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized</population>
        <group_list>
          <group group_id="O1">
            <title>SPD489</title>
            <description>SPD489: Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Columbia-Suicide Severity Rating Scale (C-SSRS)</title>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) at 52 Weeks</title>
        <time_frame>Baseline and 52 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized</population>
        <group_list>
          <group group_id="O1">
            <title>SPD489</title>
            <description>SPD489: Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Calgary Depression Scale for Schizophrenia (CDSS) at 52 Weeks</title>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Simpson Angus Scale (SAS) Total Score at 52 Weeks</title>
        <time_frame>Baseline and 52 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized</population>
        <group_list>
          <group group_id="O1">
            <title>SPD489</title>
            <description>SPD489: Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Simpson Angus Scale (SAS) Total Score at 52 Weeks</title>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Barnes Akathisia Scale (BAS) Total Score at 52 Weeks</title>
        <time_frame>Baseline and 52 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized</population>
        <group_list>
          <group group_id="O1">
            <title>SPD489</title>
            <description>SPD489: Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Barnes Akathisia Scale (BAS) Total Score at 52 Weeks</title>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the Abnormal Involuntary Movement Scale (AIMS) at 52 Weeks</title>
        <time_frame>Baseline and 52 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized</population>
        <group_list>
          <group group_id="O1">
            <title>SPD489</title>
            <description>SPD489: Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in the Abnormal Involuntary Movement Scale (AIMS) at 52 Weeks</title>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Clinical Evaluation of Harmful Behavior (CEHB) Scale at 52 Weeks</title>
        <time_frame>Baseline and 52 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized</population>
        <group_list>
          <group group_id="O1">
            <title>SPD489</title>
            <description>SPD489: Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Clinical Evaluation of Harmful Behavior (CEHB) Scale at 52 Weeks</title>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Amphetamine Cessation Symptom Assessment (ACSA) Total Score at 52 Weeks</title>
        <time_frame>Baseline and 52 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized</population>
        <group_list>
          <group group_id="O1">
            <title>SPD489</title>
            <description>SPD489: Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Amphetamine Cessation Symptom Assessment (ACSA) Total Score at 52 Weeks</title>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Negative Symptom Assessment (NSA-16) Total Score at 52 Weeks</title>
        <time_frame>Baseline and 52 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized</population>
        <group_list>
          <group group_id="O1">
            <title>SPD489</title>
            <description>SPD489: Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Negative Symptom Assessment (NSA-16) Total Score at 52 Weeks</title>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Personal and Social Performance (PSP) Scale Score at 52 Weeks</title>
        <time_frame>Baseline and 52 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized</population>
        <group_list>
          <group group_id="O1">
            <title>SPD489</title>
            <description>SPD489: Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in the Personal and Social Performance (PSP) Scale Score at 52 Weeks</title>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression-Schizophrenia Severity of Illness (CGI-SCH-S) Scale</title>
        <time_frame>Baseline and week 52</time_frame>
        <safety_issue>No</safety_issue>
        <population>Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized</population>
        <group_list>
          <group group_id="O1">
            <title>SPD489</title>
            <description>SPD489: Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Clinical Global Impression-Schizophrenia Severity of Illness (CGI-SCH-S) Scale</title>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression-Schizophrenia Degree of Change (CGI-SCH-C) Scale</title>
        <time_frame>Up to 52 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized</population>
        <group_list>
          <group group_id="O1">
            <title>SPD489</title>
            <description>SPD489: Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Clinical Global Impression-Schizophrenia Degree of Change (CGI-SCH-C) Scale</title>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Social Functioning Scale (SFS) at 52 Weeks</title>
        <time_frame>Baseline and 52 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized</population>
        <group_list>
          <group group_id="O1">
            <title>SPD489</title>
            <description>SPD489: Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Social Functioning Scale (SFS) at 52 Weeks</title>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a multicenter publication is not submitted within twelve (12) months after conclusion, abandonment or termination of the Study at all sites, or after Sponsor confirms there shall be no multicenter Study publication, the Institution and/or such Principal Investigator may publish the results from the Institution site individually.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Study Physician</name_or_title>
      <organization>Shire</organization>
      <phone>+1 866 842 5335</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
